Vipal Durkal, MD

hematology oncologist

Baylor College of Medicine and community oncology practice in the Houston area

Published Articles (1)

Early Relapse DLBCL: A Case-Based Guide to CAR T-Cell Referral, Product Selection, and Post-CAR-T Sequencing

September 7, 2026

Early relapse diffuse large B-cell lymphoma (DLBCL), defined as relapse within 12 months of frontline therapy, should prompt evaluation for second-line CAR T-cell therapy rather than default salvage chemotherapy and transplant.